Building on the U.S.–U.A.E. Business Council’s previous reports on the U.A.E.’s healthcare and life
sciences sector, this updated edition provides U.S. companies with the latest insights needed to engage
in the next phase of the country’s healthcare and life sciences development. This February 2026 report
underscores the U.A.E.’s accelerated adoption of digital health and biotechnology, with particular
emphasis on advancements in personalized medicine, preventive care, genomics, pre-clinical and
clinical trial activity, domestic pharmaceutical manufacturing, and the continued build-out of medical
and healthcare infrastructure.

This report provides a snapshot of both challenges and opportunities for our member companies in the
U.A.E. healthcare market and offers resources for businesses entering the market. This report provides
an overview of the latest developments and the potential for growth of the U.A.E. healthcare market,
government reforms necessary to meet the demands of this evolving ecosystem, both from a regulatory
and service provision perspective, and the steps that the government is taking to meet these demands.
Secondly, this report takes a closer look at the different actors and entities in the U.A.E. healthcare
sector – from regulators to providers, insurers to manufacturers, researchers to educators, and others
that are driving this rapid change.